• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤细胞内在 CTLA4 调控非小细胞肺癌中的 PD-L1 表达。

Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Diego, La Jolla, California.

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

J Cell Mol Med. 2019 Jan;23(1):535-542. doi: 10.1111/jcmm.13956. Epub 2018 Oct 30.

DOI:10.1111/jcmm.13956
PMID:30378264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6307812/
Abstract

Cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1) are immune checkpoint proteins expressed in T cells. Although CTLA4 expression was found in multiple tumours including non-small cell lung cancer (NSCLC) tissues and cells, its function in tumour cells is unknown. Recently, PD-1 was found to be expressed in melanoma cells and to promote tumorigenesis. We found that CTLA4 was expressed in a subset of NSCLC cell lines and in a subgroup of cancer cells within the lung cancer tissues. We further found that in NSCLC cells, anti-CTLA4 antibody can induce PD-L1 expression, which is mediated by CTLA4 and the EGFR pathway involving phosphorylation of MEK and ERK. In CTLA4 knockout cells, EGFR knockout cells or in the presence of an EGFR tyrosine kinase inhibitor, anti-CTLA4 antibody was not able to induce PD-L1 expression in NSCLC cells. Moreover, anti-CTLA4 antibody promoted NSCLC cell proliferation in vitro and tumour growth in vivo in the absence of adaptive immunity. These results suggest that tumour cell-intrinsic CTLA4 can regulate PD-L1 expression and cell proliferation, and that anti-CTLA4 antibody, by binding to the tumour cell-intrinsic CTLA4, may result in the activation of the EGFR pathway in cancer cells.

摘要

细胞毒性 T 淋巴细胞相关抗原 4(CTLA4)和程序性细胞死亡蛋白 1(PD-1)是 T 细胞表达的免疫检查点蛋白。尽管 CTLA4 在包括非小细胞肺癌(NSCLC)组织和细胞在内的多种肿瘤中均有表达,但它在肿瘤细胞中的功能尚不清楚。最近发现 PD-1 在黑色素瘤细胞中表达,并促进肿瘤发生。我们发现 CTLA4 在一组 NSCLC 细胞系和肺癌组织中的一部分癌细胞中表达。我们进一步发现,在 NSCLC 细胞中,抗 CTLA4 抗体可诱导 PD-L1 表达,这是由 CTLA4 和涉及 MEK 和 ERK 磷酸化的 EGFR 途径介导的。在 CTLA4 敲除细胞、EGFR 敲除细胞或存在 EGFR 酪氨酸激酶抑制剂的情况下,抗 CTLA4 抗体不能诱导 NSCLC 细胞中 PD-L1 的表达。此外,抗 CTLA4 抗体在不存在适应性免疫的情况下促进 NSCLC 细胞在体外的增殖和体内肿瘤的生长。这些结果表明,肿瘤细胞内在 CTLA4 可以调节 PD-L1 的表达和细胞增殖,并且抗 CTLA4 抗体通过与肿瘤细胞内在 CTLA4 结合,可能导致癌细胞中 EGFR 途径的激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/5963f8d4a8fd/JCMM-23-535-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/6785bec4bf9b/JCMM-23-535-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/b902a1da7a89/JCMM-23-535-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/72afe4e474f9/JCMM-23-535-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/5963f8d4a8fd/JCMM-23-535-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/6785bec4bf9b/JCMM-23-535-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/b902a1da7a89/JCMM-23-535-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/72afe4e474f9/JCMM-23-535-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c43/6307812/5963f8d4a8fd/JCMM-23-535-g004.jpg

相似文献

1
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.肿瘤细胞内在 CTLA4 调控非小细胞肺癌中的 PD-L1 表达。
J Cell Mol Med. 2019 Jan;23(1):535-542. doi: 10.1111/jcmm.13956. Epub 2018 Oct 30.
2
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
3
Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.缺氧诱导因子-1α 和核因子-κB 在调节非小细胞肺癌细胞中表皮生长因子受体突变体程序性细胞死亡配体 1 的表达中发挥重要作用。
Cancer Sci. 2019 May;110(5):1665-1675. doi: 10.1111/cas.13989. Epub 2019 Mar 23.
4
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).表皮生长因子受体(EGFR)通路、Yes 相关蛋白(YAP)与非小细胞肺癌(NSCLC)中程序性死亡配体 1(PD-L1)的调控。
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
5
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.PD-L1诱导的BAG-1增加通过持续激活ERK信号通路赋予非小细胞肺癌对酪氨酸激酶抑制剂的抗性。
Eur J Cancer. 2017 Nov;85:95-105. doi: 10.1016/j.ejca.2017.07.025. Epub 2017 Sep 9.
6
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体的突变激活通过细胞外信号调节激酶下调主要组织相容性复合物 I 类的表达。
Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.
7
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物(ATLANTIC):一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
8
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.经典的 TGF-β/Smad 信号通路参与了 EGFR 突变型非小细胞肺癌中 PD-L1 诱导的 EGFR-TKIs 原发性耐药。
Respir Res. 2019 Jul 22;20(1):164. doi: 10.1186/s12931-019-1137-4.
9
CD147-mediated glucose metabolic regulation contributes to the predictive role of F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC.CD147 介导的葡萄糖代谢调控有助于 F-FDG PET/CT 成像预测 NSCLC 患者对 EGFR-TKI 治疗敏感性的作用。
Mol Carcinog. 2019 Feb;58(2):247-257. doi: 10.1002/mc.22923. Epub 2018 Oct 25.
10
DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.DRD1 抑制非小细胞肺癌细胞增殖,并降低 EGFR 激活和 PD-L1 表达。
Mol Oncol. 2024 Jun;18(6):1631-1648. doi: 10.1002/1878-0261.13608. Epub 2024 Apr 4.

引用本文的文献

1
Breaking barriers: exploring blood-brain barrier crossing mechanisms with nanomedicine for effective glioma treatment.突破障碍:利用纳米医学探索血脑屏障穿越机制以实现有效的胶质瘤治疗。
3 Biotech. 2025 Jul;15(7):213. doi: 10.1007/s13205-025-04378-3. Epub 2025 Jun 13.
2
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.非小细胞肺癌肿瘤微环境特异性疗法的现状
Cancers (Basel). 2025 May 22;17(11):1732. doi: 10.3390/cancers17111732.
3
Novel Chimeric CTLA-4 B-cell Epitope Peptide Vaccines Demonstrate Effective Antitumor Immunity with/without PD1/PDL1 Blockade in Multiple Syngeneic Murine Models of Breast and Colorectal Cancers.

本文引用的文献

1
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.抑制 yes 相关蛋白下调人恶性胸膜间皮瘤中 PD-L1(CD274)的表达。
J Cell Mol Med. 2018 Jun;22(6):3139-3148. doi: 10.1111/jcmm.13593. Epub 2018 Mar 24.
2
YAP regulates PD-L1 expression in human NSCLC cells.YAP调节人非小细胞肺癌细胞中PD-L1的表达。
Oncotarget. 2017 Dec 9;8(70):114576-114587. doi: 10.18632/oncotarget.23051. eCollection 2017 Dec 29.
3
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
新型嵌合CTLA-4 B细胞表位肽疫苗在多种乳腺癌和结直肠癌同基因小鼠模型中,无论有无PD1/PDL1阻断,均表现出有效的抗肿瘤免疫。
Mol Cancer Ther. 2025 Sep 2;24(9):1362-1377. doi: 10.1158/1535-7163.MCT-24-0908.
4
Neuregulin-1 prevents death from a normally lethal respiratory viral infection.神经调节蛋白-1可预防因通常具有致命性的呼吸道病毒感染导致的死亡。
PLoS Pathog. 2025 Apr 23;21(4):e1013124. doi: 10.1371/journal.ppat.1013124. eCollection 2025 Apr.
5
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.大麻素对接受免疫检查点抑制剂免疫治疗的患者癌症预后的影响。
Front Immunol. 2025 Mar 5;16:1497829. doi: 10.3389/fimmu.2025.1497829. eCollection 2025.
6
Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer.基于超顺磁性氧化铁纳米颗粒/miR-497的新型诊疗纳米载体用于靶向结直肠癌的制备
Sci Rep. 2025 Feb 4;15(1):4247. doi: 10.1038/s41598-025-88165-3.
7
Role of CTLA4 and pSTAT3 Immunostaining in Prognosis and Treatment of the Colorectal Carcinoma.CTLA4和磷酸化信号转导与转录激活因子3免疫染色在结直肠癌预后及治疗中的作用
Iran J Pathol. 2024 Winter;19(1):89-102. doi: 10.30699/IJP.2024.2009619.3158. Epub 2024 Mar 29.
8
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.从免疫检查点到治疗方法:了解免疫检查点调控以及天然产物和传统医学对肺癌免疫检查点和免疫治疗的影响。
Front Immunol. 2024 Feb 15;15:1340307. doi: 10.3389/fimmu.2024.1340307. eCollection 2024.
9
The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.抗CD47抗体与CTLA4阻断剂联合使用通过肿瘤血管正常化和免疫微环境重编程增强非小细胞肺癌的抗肿瘤免疫力。
Cancers (Basel). 2024 Feb 19;16(4):832. doi: 10.3390/cancers16040832.
10
Interaction between NSCLC Cells, CD8 T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling-New Cues on CAT-VTE.非小细胞肺癌细胞、CD8 T 细胞与免疫检查点抑制剂的相互作用增强了凝血作用,并促进了代谢重编程——CAT-VTE 的新线索。
Cells. 2024 Feb 7;13(4):305. doi: 10.3390/cells13040305.
纳武利尤单抗与伊匹木单抗联合用药对比伊匹木单抗单药治疗晚期黑色素瘤患者:一项多中心、随机、对照、2期试验的2年总生存结果
Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.
4
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.致癌激活 AKT-mTOR 通路对非小细胞肺癌 PD-L1 表达的调控。
Cancer Res. 2016 Jan 15;76(2):227-38. doi: 10.1158/0008-5472.CAN-14-3362. Epub 2015 Dec 4.
5
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.黑色素瘤细胞内在的PD-1受体功能促进肿瘤生长。
Cell. 2015 Sep 10;162(6):1242-56. doi: 10.1016/j.cell.2015.08.052.
6
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.人类癌症的抗PD-1/PD-L1疗法:过去、现在与未来。
J Clin Invest. 2015 Sep;125(9):3384-91. doi: 10.1172/JCI80011. Epub 2015 Sep 1.
7
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.纳武利尤单抗与伊匹木单抗联合治疗对比伊匹木单抗单药治疗未经治疗的黑色素瘤
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
8
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
9
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1(PD-1)阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
10
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.